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Abstract
The purpose of this study was to investigate isokinetic strength, quality of life, range of
motion, and calf circumference for patients with acute Achilles tendon rupture treated nonoperatively with accelerated functional rehabilitation with or without Autologous
Conditioned Plasma (ACP®).
We used a cohort of patients (n=34) from a published randomized trial to serve as our
historical control group. We recruited 51 consecutive patients and administered two ACP®
injections during the first four weeks post injury.
The mean between groups difference in plantar flexion strength (injured/uninjured) at one
year post injury was 2.9% (95% Cl -13.6 to 7.8), p = 0.6 and -0.3% (95% Cl -13.6 to 13.0), p
= 1.0 at 30°/s and 607s respectively. All secondary outcomes were also not different.
The addition of ACP to a non-operative treatment protocol with accelerated functional
rehabilitation does not provide better outcomes at one year post Achilles tendon rupture.
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Chapter 1: Introduction

Rupture of the Achilles tendon is one of the most common tendon injuries in the adult
population. The incidence of Achilles tendon injury is increasing as aging adults continue
to participate in high demand sports 44 S4' 74 such as basketball, racquet sports, soccer, etc.
There is debate about the most effective treatment of Achilles tendon ruptures; some
arguing for operative repair while others argue for a non-operative approach. In a
randomized clinical trial of 144 patients, Willits et al (2010)112 found that the strength,
similar to outcomes reported by 72 patients who were treated with operative repair. In a
systematic review of the literature, they found similar conclusions whenever the non
operative treatment entailed early mobilization110.
Recently platelet-rich plasma (PRP) was introduced as a new treatment option for
orthopedic injuries22' 24' 24 72 ss. PRP is defined as a concentration of platelets in plasma
that is greater than the baseline concentration67. Platelets are a type of white blood cell
that contains more than 30 bioactive proteins, many of which have a fundamental role in
haemostasis or tissue healing". The intended purpose of PRP is to create an optimal
healing environment by isolating the plasma components from an individual's blood and
injecting it at the site of injury.
Platelet rich plasma (PRP) has many names throughout the literature; autologous
conditioned plasma (ACP®), platelet enriched plasma (PeRP), platelet-rich concentrate
(PRC), preparation rich in growth factors (PRGF), autogenous platelet gel, or platelet
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range of motion and patient-reported function in 72 patients treated non-operatively were
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releasate2'67' 90. The variation in name is dependent on the concentration of plasma, the
preparation system, the addition of anticoagulants, or the addition of activating agents. In
our study we used autologous conditioned plasma (ACP®) as prepared by the Arthrex
Bio Systems™ (Arthrex, Inc., Naples, Florida).
On February 17, 2009 the New York Times reported that two of the Pittsburgh Steelers
football players had used their own blood (PRP) to accelerate the healing time of their
injuries (a calf muscle strain in one athlete and a medial collateral ligament sprain in the
other). According to the article, these injuries should have kept these athletes sidelined
game and the team won the NFL championship.
A recent systematic review by Taylor et al (2011) , evaluated outcomes following the
use of PRP for the treatment of tendon and ligament injuries in vivo and in humans. The
authors found three randomized studies; three prospective cohort studies; and seven casereports or case-control studies that met their inclusion criteria. Eight of these studies
reported favorable outcomes for pain, functional scores, range of motion and return to
activity with the use of PRP, (one of these was a randomized trial). The other studies
reported no significant benefits to the use of PRP.
With respect to studies that have evaluated the use of PRP for Achilles tendon tears,
Sanchez et al (2007)Sii published a case-control study where six athletes with complete
Achilles tendon tears underwent open suture repair augmented with a preparation rich in
growth factors (PRGF). Range of motion, functional recovery, complications, and crosssectional area of these six athletes were compared to a matched group of six athletes who

A u v u a n o ift n

for the Super Bowl game. Following the injection however, both athletes played in the
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had the same injury and received the same treatment with the exception of the PRGF
injection. Athletes receiving PRGF recovered their ankle range of motion earlier (7 +/- 2
weeks vs 11 +/- 3 weeks, p = 0.03) (Mean diff. = 4; Cl 95% 0.72 to 7.28, p = 0.02),
showed no wound complication, were permitted by their surgeon to take up gentle
running more quickly ( 11 +/- 1 weeks vs 18 +/- 3 weeks, p = 0.04) (Mean diff. = 7; Cl
95% 4.12 to 9.88 p < 0.01), and to resume training activities ( 14 +/- 0.8 weeks vs 21 +/- 3
weeks, p < 0.01 ) (Mean diff = 7.0; Cl 95% 4.18 to 9.82 p < 0.01).
To date, there has been no study investigating the effects of applying ACP® to an acute
Thus, this study is a prospective cohort study with historical control group to compare the
one year outcomes following non-operative treatment of patients with an acute Achilles
tendon rupture treated with or without ACP® injection, the first study of its kind to date.
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Chapter 2: Literature Review

2.1 Functional Anatomy of the Achilles Tendon
2.1.1

Histology of the Achilles Tendon

Tendons are anatomic structures interposed between muscles and bones transmitting the
force created in the muscle to bone, and, in this way, making joint movement possible46.
Tendons are stiff and resilient, with high tensile strength: they can stretch up to 4%
the cellular elements of the tendon, with chondrocytes, vascular cells, synovial cells and
smooth muscle cells forming the remaining 5-10%23. Tenocytes and tenoblasts produce
collagen and elastin, and these in turn are organized in a complex hierarchical scheme to
form the tendon proper46. Tendons consist of collagen (mostly type I collagen) and elastin
as part of the extracellular matrix, embedded in a proteoglycan-water matrix with
collagen accounting for 65-80% and elastin approximately 1-2% of the dry mass of the
tendon46.
A fine sheath of connective tissue called endotenon invests each collagen fiber and binds
fibers together. A bunch of collagen fibers forms a primary fiber bundle, and a group of
primary fiber bundles forms a secondary fiber bundle. A group of secondary fiber
bundles, in turn, forms a tertiary bundle, and the tertiary bundles make up the tendon46.
The entire tendon is surrounded by a fine connective tissue sheath called epitenon46. The
epitenon in turn is surrounded by paratenon. The paratenon and epitenon are separated by
a thin layer of fluid to reduce friction during tendon motion23.

A u v u a n o fw n

before damage23. Tenocytes (specialized fibrocytes) and tenoblasts comprise 90-95% of
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2.1.2

Muscles contributing to the Achilles tendon

Cohen (2009)|,, describes the Achilles tendon as the largest and most powerful tendon in
the ankle, while Doral et al (2009)25 adds that it is the strongest and thickest tendon in the
human body. It is also one of the most commonly torn tendons . The gastrocnemius and
soleus muscle tendons join in their distal portions to form the Achilles tendon (Figure
l)19’33.
Figure 1 Muscles of the Achilles tendon
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The gastrocnemius is a fusiform muscle composed of medial and lateral heads 19’25’33 .
The gastrocnemius is the most superficial muscle of the dorsal aspect of the lower leg and
gives the calf its characteristic bulge25. The origin of the gastrocnemius is from the
posterior aspect of the distal femoral condyles. Both heads of the gastrocnemius cross the
knee joint25. The gastrocnemius is considered a flexor of the knee and a plantar flexor of

6

the ankle, and produces the maximal moment of force during contraction with the ankle
plantar flexed and the knee extended. The main function of the gastrocnemius muscle is
to supply power for propulsion of the body forward during gait19 ".
The solcus muscle has a complex multipennate architecture19. Two separate
compartments, a bipennate anterior compartment and a unipennate posterior
compartment, can be identified within the soleus muscle'9. The soleus muscle originates
from the posterior aspects of the tibia and fibula at their proximal ends. It acts only on
the ankle joint and can be palpated on either side of the gastrocnemius when the subject
produces the maximal force during contraction with the ankle plantar flexed and the knee
flexed. The soleus is a postural muscle that also acts as a peripheral vascular pump19.

2.1.3

Tendinous formation of the Achilles tendon

In their distal aspects, both the gastrocnemius and the soleus muscles form an
aponeurosis, from each of which originates a tendon19. These two tendons freely glide
independently before they coalesce into the Achilles tendon, approximately 5 to 6 cm
proximal to the calcaneal insertion19'2'. The tendinous components of these two muscles
are variable. The gastrocnemius component is longer (11-26 cm) than that of the soleus
(3-11 cm)92. Fibers from the medial head of the gastrocnemius muscle pass laterally and
posteriorly, whereas the fibers from the lateral head of the gastrocnemius muscle reach
the anterior surface of the tendon100. Szaro et al (2009)'°° also found that the deep part of
the tendon was formed by fibers from the lateral head of the gastrocnemius muscle and
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stands on their tiptoes '. The soleus muscle as part of the gastroc-soleus complex and
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the soleus muscle. The superficial layer of the tendon is formed by the fibers from the
medial head of the gastrocnemius and soleus muscles ioo.
The superficial crural fascia also contributes fibers to the Achilles tendonl9. The Achilles
tendon is larger at the insertion on the inferior half of the posterior calcaneal surface19.
The average length of the Achilles tendon is 15cm and ranges from 11 to 26cm 1525
" ’100
The mean width of the Achilles tendon is 6.8cm (4.5 - 8.6cm) at its origin, gradually
becoming thinner at the midsection being 1.8cm (1.2 - 2.6cm)4. It then becomes rounded
until approximately 4cm above the calcaneus before expanding" ’ . The mean width of
surface of the calcaneus4.
The Achilles tendon is rounded proximally and relatively flat distally19. Approximately
12 - 15cm proximal to its insertion (at about the level where the soleus contributes fibers
to the Achilles tendon), rotation begins and becomes more marked in the distal five to six
centimeters19'23. Rotation of the fibers from the Achilles tendon has been described as
twisting 90 degrees counterclockwise toward the insertion into the calcaneal tuberosity33.
The degree of rotation of the tendon is variable, ranging between 30 to 150 degrees19.

2.1.4

Blood and Nerve Supply to the Achilles Tendon

The Achilles tendon receives its blood supply from three regions. It comes from the
intrinsic vascular systems at (1) the musculotendinous junction, (2) the osteotendinous
junction, and from the extrinsic segmental vascular system through (3) the paratenon
surrounding the tendon1' l(). Nerves and blood vessels run through the paratenon, which is
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the main blood supply to the middle portion of the tendon19. This supply comes through a
series of venicula, which function as passageways for blood vessels to reach the tendon19.
A recurrent branch of the posterior tibial artery supplies the proximal part of the tendon,
whereas the distal part is vascularized by the rete arteriosum calcaneare and supplied by
the fibular and posterior tibial arteries' l9. There is an area of relative avascularity in the
Achilles tendon 2-6 cm above its insertion ' . Dorai et al (2009) suggests that it is due
to the structure of the blood supply that there is a relatively hypovascular area in the midI

portion of the tendon where most problems occur.
The Achilles tendon is supplied by nerves from the attaching muscles and by small
the tibial nerve2s.

2.1.5

Related structures

The site at which a tendon, ligament or joint capsule attaches to bone is known as an
enthesis94. This attachment is often part of a collection of tissues jointly called an
‘enthesis organ’. The purpose of this organ is to reduce stress concentration at the hardsoft tissue interface94. The insertion of the Achilles tendon is part of such an ‘enthesis
organ’. The organ also includes opposing sesamoid and periosteal fibrocartilages, a bursa
and Kager’s fat pad.
There is a retrocalcaneal bursa that lies deep and just proximal to the insertion of the
Achilles tendon, between the posterior calcaneal tuberosity and the tendon19. Superficial
to the tendon, the pre-Achilles bursa lies between the tendon and the skin. This bursa is

U.W.O. LIBRARY
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composed of synovium and provides lubrication to assist with tendon gliding and to
minimize tendon irritation19.
The Achilles tendon is surrounded by a paratenon which is a double-layered sheath
composed of an inner, visceral layer and an outer, parietal layer. The tendon has no true
synovial sheath19. Nerves and blood vessels run through the paratenon, which is the main
blood supply to the middle portion of the tendon19. Deep to the paratenon, the Achilles
tendon is surrounded by the epitenon, a fine, smooth connective tissue sheath. The inner
surface of the epitenon is continuous with the endotenon, which binds the collagen fibers
tendon*4.

2.2 Achilles Tendon Rupture
2.2.1

Epidemiology

The following studies summarize the incidence and patient population associated with
acute Achilles tendon ruptures.
Leppilahti et al (1996)S4 determined the incidence of Achilles tendon rupture in the city
of Oulu, Finland over a 16 year period (1979 to 1994). During this period 111 ruptures
occurred in 110 individuals. The incidence increased from two ruptures per 10s
inhabitants in 1979 to 1986, to 12 in 1987 to 1994. The annual incidence after 1985
increased more in men (94) than in women (17). There was also a greater rise in
incidences in sports-related injuries (90) than non-sports-related injuries (21). The peak
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age-specific annual rupture incidence was in the age group 30 to 39 years (r = 0.74, p <
0 .01 ).

Moller et al (1996)74 researched the incidence of Achilles tendon rupture in the city of
Malmo, Sweden from 1987 to 1991. They found 153 diagnosed cases. They found the
highest incidence in the age group of 30 to 39 with an incidence of 30.4 per 100, 000
inhabitants, followed by the 40 to 49 age group with an incidence of 26.2 per 100, 000
inhabitants. The average age of men was 42 (20-80) years and of women 52 (25-80) years
(p < 0.01). Sports injuries (98) were almost twice as common as other injuries (55), and
group (men = 97, women = 7). Badminton, soccer and tennis were most common
amongst sports injuries.
Houshian et al (1998)40 studied the incidence of Achilles tendon ruptures in a Danish
county from 1984-1996. There were 718 ruptures, 544 men (75.8%) and 174 women
(24.2%). The average age was 42.1 years (3-82) and 62% were between 30^19 years.
74.2% of the ruptures were sport-related and 89% of these occurred in ball and racket
games. The annual incidence of Achilles tendon ruptures increased from 18.2 per 100,
000 inhabitants in 1984 to 37.3 per 10s in 1996 (r = 0.63, p < 0.05). The peak incidence
in sport-related ruptures occurred in the age group 30-49 years, but ruptures not related
to sport occurred in older patients with a peak incidence in those 50-59 years.
Jozsa et al (1989)44 completed a review of 749 patients who had 832 various tendon
ruptures treated surgically, 292 cases of which were Achilles tendon ruptures, between
1972 and 1985. Their goal was to evaluate the role of recreational sport activity in
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incidence was greater in men (132) than women (21), especially in the sports injuries
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Achilles tendon rupture. They found that 59% of Achilles tendon ruptures occurred in
recreational sports activities in contrast to two percent in other tendon ruptures (p <
I

1

0.01). The mean age for patients with Achilles tendon ruptures was 35.2 years, and 50.7
years in those with other ruptures (p < 0.01). Amongst the patients with Achilles tendon
ruptures, 82.9% were male, and 18.1% were female.
Summary: Achilles tendon ruptures are most common in the male population, those
aged between 30 and 39, and are more likely to occur during recreational sports activities.
There also appears to be an increase in incidence over those time periods studied.

Mechanism of Injury

Sudden force application (resulting in a larger than usual force being applied rapidly to
I

the tendon), typically involving eccentric muscle contraction, may lead to muscle or
tendon injuryPatients with Achilles tendon ruptures usually report a sudden, painful
pop or snap in their calf with subsequent weakness and gait disturbances39 .
Wapner (2011)109 describes the mechanism of injury for an Achilles tendon rupture as
occurring at a moment of deceleration. It often occurs when the gastrocnemius muscle
forcibly retracts, as when one lands on the ground after going up for a rebound in
basketball, causing a sudden and unexpected dorsi flexion of the ankle. They also occur
while pushing off with the knee extended, such as in tennis when an individual lunges for
a shot. Another mechanism is with a sudden violent dorsi flexion force on a plantar
flexed foot. All of these mechanisms result in an eccentric muscle contraction by the
gastroc-soleus complex as this unit resists forceful dorsi flexion of the ankle. These
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traumatic ruptures occur because the force exerted on the suddenly rapidly loaded tendon
exceeds the tendon’s tensile strength109.

I

2.2.3

Causes of and Predisposition to Rupture

Chen et al (2009)16 proposes that multiple factors are involved in the pathogenesis of
tendon rupture. Possible risk factors of Achilles tendon rupture apart from direct trauma,
include ageing, underlying tendon degeneration (inflammatory, microtrauma), the use of
corticosteroids - (local/systemic), and the use of fluoroquinolones6'49'47'59,71'98.

predisposing factor to Achilles tendon rupture, which others16 have suggested is due to
the hypovascular region found in the tendon. Chronic tendinitis as a result of overuse or
overload of the Achilles tendon may consist of microtears of the tendon which may lead
to injury16. A watershed region of decreased vascularity has been noted in a number of
studies, located approximately two to six centimeters proximal to the calcaneal insertion
of the tendon, and is a common location of Achilles tendon lesions10'91. The use of
fluroquinolone antibiotics has been associated with Achilles tendon rupture through an
unknown mechanism ’ .
Chazan (1998)15 proposes that the structure of the Achilles tendon as it twists from
proximal to its distal insertion may predispose it to rupturel5. Heckman et al (2009)41
suggest that a cavus foot or a flat foot with excessive pronation, as well as malalignment
factors above the ankle, such as genu varum, can also contribute to increased stress on the
Achilles tendon92. Finally, Schepsis et al (2002)92 demonstrated that Achilles tendon
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Josza et al (1997)43 found degenerative changes in the tendon, like tendinitis, as a
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injuries are frequently encountered in individuals who participate in strenuous physical
activities that involve repetitive, eccentric, impact loading and jumping34.

2.2.4

Diagnosis and Clinical Presentation

Patients with acute Achilles tendon rupture describe the sensation as feeling like they had
been hit in the back of the ankle or calf. This is followed by intense pain, and the inability
to bear weight due to weakness of the calf and inability to plantar flex the ankle. The
Simmonds’ test, also known as the Thompson test, is a gross screening examination for
an Achilles tendon rupture often used as a diagnosis for complete Achilles tendon
rupture1' ' 101. The patient lies prone on the examination table with the feet and ankles
positioned over the edge of the table. In a person with an intact Achilles tendon, the foot
should move into plantar flexion when you squeeze the calf muscles bilaterally. No
diagnostic tool in the evaluation of acute Achilles tendon rupture12.
The foot on the affected leg is maintained in a plantar flexed position when the patient
sits on the examination table. Patients often present with swelling in the posterior ankle,
foot and toes. Subjectively reported pain levels can be variable11'26.
Harris et al (2006)3S describes full thickness tears or rupture as that which involves the
entire cross-section of the tendon with a gap between the retracted torn tendon ends. The
examiner can often feel the defect when palpating the contour and shape of the Achilles
tendon11’39.
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movement in the foot indicates a rupture". Ultrasound has also been commonly used as a
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2.2.4.1

Assessment of Achilles Tendon Rupture

Maffulli (1998)ss completed a study to determine the sensitivity, specificity, and positive
and negative predictive values of several clinical diagnostic tests of subcutaneous
Achilles tendon ruptures, including: palpation for the presence of a gap; calf squeeze for
presence of plantar flexion of the ankle; Matles test for comparison of the amount of
plantar flexion in the affected leg when compared with the unaffected while patient lies
prone and both knees are flexed to 90°; Copeland test which looks for a rise in pressure
around the calf using a sphygmomanometer and passively dorsi flexing the ankle with the
knee in 90° flexion; and the O'Brien test which looks at the movement of a needle placed
patients with complete rupture and 28 with suspected but no actual tears. They found the
Matles test and calf squeeze test (Thompson test) to be significantly more sensitive than
the other tests (0.022 < p < 0.05).
Leppilahti et al (1998)53 compiled a clinical scoring scale which was the first
standardized protocol for evaluation of repaired Achilles tendon ruptures. It consists of
subjective assessment of the symptoms (pain, stiffness, muscle weakness, footwear
restrictions), clinical evaluation of ankle range of motion, overall patient satisfaction, and
isokinetic calf muscle strength (plantar and dorsi flexion). The authors applied the system
to a large series of patients, analyzing the prognostic factors related to the results at 3.1
years after surgery with a six week cast immobilization post surgery. Their study
included 101 patients, 21 of which were professional athletes and 70 of which were
recreational athletes. Authors found patient characteristics associated with unsatisfactory
strength results were lower activity levels, presence of systemic diseases, and a later
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return to physical exercise. An older age and later return to physical activity were
associated with unsuccessful or lower overall results.
Martin et al (2005)65 completed a review of the existing range-of-motion measurement
literature related to ankle dorsi flexion and plantar flexion to determine whether the
reliability of ankle range-of-motion measurements can be defined, how the characteristics
of the study population or clinician affect reliability, and the level of responsiveness for
these measures. Eleven articles met their inclusion criteria. Authors were unable to pool
results for the studies as the methods used for each varied greatly. Authors did find
reliability for ankle dorsi flexion. Authors also concluded that the responsiveness of ankle
joint range of motion measurements is uncertain and requires further studies using patient
populations.
Moller et al (2005)75completed a study to investigate the reliability of different methods
used for isokinetic testing of calf muscle strength and endurance. Ten healthy subjects
volunteered for the study and were tested for isokinetic plantar and dorsi flexion strength
using a dynamometer in three positions: seated with the hip at 110° flexion and the knee
at 90° flexion, seated with the hip and knee at 90° flexion, and supine with hip and knee
at neutral (full extension). An endurance test was performed with a test device for the
standardized counting of heel raises. Passive and active ankle range of motion was
measured with a goniometer, calf circumference with a tape measure, and tendon width
was measured with a vernier caliper. The ICCs for plantar flexion in position one (right
and left side) were 0.37-0.95. The corresponding values in position two (right and left
side) were 0.53-0.85. In position three (right and left side), the ICC values for plantar
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evidence for intra-rater reliability for plantar and dorsi flexion, as well as inter-rater
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flexion ranged from 0.61-0.91. The test-retest reliability of the isokinetic measurements
of dorsi flexion, measured as ICC, in position one (right and left side) was 0.34-0.96 .
The corresponding values in position two (right and left side) were 0.00-0.83. The
reliability expressed as ICC was found to be 0.78-0.84 for the endurance test, 0.97-0.98
for the calf circumference, 0.84-0.87 for the tendon width and 0.71-0.91 for the range of
motion. Authors concluded that the test-retest reliability was acceptable for all the
methods that were employed.
In 2007, Nilsson-Helander et al79 developed and evaluated the Achilles tendon rupture
for Achilles tendon rupture which includes 10 questions related to strength, fatigue,
stiffness, pain and activities. The ATRS was tested for validity, structure, and internal
consistency (Cronbach's alpha) on 82 patients and 52 healthy persons. Authors
performed a correlation analysis with the two validated foot/ankle/Achilles tendon scores,
the Foot and Ankle Outcome Score (FAOS) and the Swedish version of the Victorian
Institute of Sports Assessment-Achilles questionnaire (VISA-A-S). Structure was
evaluated with factor analysis. Test-retest reliability was evaluated on 43 patients. The
ATRS responsiveness was tested on 43 patients by calculating the effect size. The total
score for the patients ranged from 17 to 100 with a mean of 77 ± 21.4. A significantly (p
< 0.01) higher total score was found for the healthy subjects, ranging from 94 to 100 with
a mean of 99.8 ±1.1. The ATRS correlated significantly (p < 0.01) with all subscales of
the FAOS (r = 0.60-0.84) and the VISA-A-S (r = 0.78). The factor analysis gave one
factor of importance. The internal consistency was 0.96 as measured with Cronbach's
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score (ATRS). It is a patient-reported instrument for measuring outcome after treatment

alpha. The test-retest produced an intraclass correlation coefficient of 0.98. The tests for
responsiveness showed an effect size between 0.87 and 2.21.

2.3 Treatment of the Achilles Tendon Rupture
2.3.1

Tendon Healing

There are three phases in tendon healing, and these phases overlap as the tissue completes
its healing. The first phase is known as the inflammatory phase and comprises
recruitment of inflammatory cells, phagocytosis of necrotic materials release of
vasoactive factors, initiation of angiogenesis, and stimulation of tenocyte proliferation113.
This is also the phase where platelet activation ' takes place through the action of the
O 'i

#

growth factors.
After a few days, the proliferative phase begins where cells proliferate and differentiate .
82

Fibroblasts become the predominant cell type during this phase {Maffulli 2000} as they
align themselves perpendicular to the long axis of the tendon. Synthesis of type III
collagen peaks during this stage, which lasts for a few weeks . Production of collagen
type I gradually takes over, and the repair callus reaches its largest size .
After approximately six to 10 weeks, the maturation or remodeling phase begins with
decreased cellularity and decreased collagen and glycosaminoglycan synthesis, and
gradual change of fibrous tissue to scar-like tendon tissue over the course of one year
{Olivia, Zafar}. During the latter half of this stage, tenocyte metabolism and tendon
vascularity decline113. Collagen type III is reabsorbed and replaced to produce better
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organization, and cross-linking increases. Finally, the callus transverse area gradually
decreases as the mechanical tissue properties improve .
82

2.3.2

History of the Treatment of Achilles Tendon Ruptures

The first description of the Achilles tendon was by Ambroise Pare in the early 1900’s49.
Polaillon performed the first reported repair of an acute Achilles tendon rupture in 1888,
and the first comparative study comparing operative versus non-operative treatment was
published by Qenu and Stoianovich in 192949. Up until the early part of the 20lh century
this condition had been managed non-operatively, but following a particular study by
management47. This study however, reported a complication rate of around 24%, which
lead a number of researchers to explore the approach of non-operative treatment47.

2.3.3

Operative Treatment

Operative repair of the ruptured Achilles tendon has been the preferred treatment by
surgeons as some studies have shown a significantly lower re-rupture rate when
compared to non-operative treatment ’ ' . However, in these studies patients in the
non-operative groups were treated with below knee casting for six to eight weeks More
recently the literature has shown that early functional rehabilitation in a below knee
orthosis can drastically reduce the rates of re-rupture72 " 2, resulting in equivalent re
rupture rates between operative and non-operative treatment.
Operative treatment of the acute Achilles tendon rupture can be done with an open or
percutaneous technique. Open surgery enables direct approximation of ruptured tendon
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Arner and Lindholm (1959)6, operative treatment became the accepted form of
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ends and an assessment of tendon length, but may disrupt the blood supply to the tendon
by damaging the paratenon48. The pereutaneous technique minimizes this complication,
but has been associated with sural nerve injury and a higher re-rupture rate™ ?7. In a
review by Khan et al (2004)48, authors established that the percutaneous technique offers
shorter operative times and lower risk of infection, but they were unable to definitively
identify the most effective surgical tendon repair technique.

2.3.4

Non-operative treatment

Complications such as wound infection or anesthetic complications have been the
primary reason behind continued focus on the non-operative versus operative
management of acute Achilles tendon rupture. Traditional non-operative treatment of
acute Achilles tendon ruptures with immobilized casting of the extremity for eight weeks
has been challenged due to functional complications such as muscle atrophy, decreased
ankle range of motion, and loss of coordination and proprioception1111. Removable
bracing with a refined rehabilitation protocol has been effective in non-operative
treatment™'l<)6' 110 ll2. The use of a heel lift in the initial stages of healing to maintain a
position of 45° to 30° plantar flexion has also been supported in the literature47 7K. The
amount of time spent immobilized after an Achilles tendon rupture has not been
definitively determined in the literature, ranging from as soon as tolerated to four
weeks86' 106' n0’61.
Karkhanis et al (2010)47 completed a retrospective study to establish the outcome of non
operative care of the Achilles tendon rupture using a removable walker boot. A noncompressible felt covered polystyrene wedge of 1cm was placed in each boot, which
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allowed 30° to 40° plantar flexion. Patient was allowed to mobilize full weight bearing as
pain would allow, initially with the help of crutches. Of the 107 patients, 98% (105/107)
reported clinical healing (no tenderness at rupture site and no palpable gap). Average
time to return to work/sports/pre-injury level of activity was seven months (3 days to 48
months). The Achilles tendon rupture score (ATRS) was completed by 56 patients via
postal correspondence, and resulted in an average of 21 out of a possible 100 (10
questions of 10 points each), where one was no limitation and 10 was complete
limitation. 77% of these patients had returned to their pre-injury level of activity. 73%
(41/56) were completely satisfied with their treatment, while 21% (12/56) were
moderately satisfied and three were not satisfied with the treatment. Authors concluded
that their protocol in functional treatment through early mobilization of non-operative
care for Achilles tendon ruptures remains a viable and successful option.

2.3.5

Operative versus Non-operative treatment: A review of the

literature
There is a great amount of literature on the comparison between operative and non
operative care of acute Achilles tendon rupture. The following are a few of these studies
comparing the differences in results in outcome of the two treatments with varying
methods in rehabilitation protocol.
Nistor et al (1981 )so completed a prospective randomized study of 105 patients to
compare the outcomes of operative versus non-operative treatment of the acute Achilles
tendon rupture. The operative group was fitted with a below-the-knee plaster cast for six
to nine weeks following surgery. During the first two to three weeks the ankle was

maintained in a position of slight plantar flexion. The non-operative group was
immobilized in a below-the-knee plaster cast in gravity plantar flexion for four weeks.
The equinus angulation was then gently reduced and another plaster cast was applied.
Immediate full-weight bearing was permitted. A 2.5cm heel-lift was placed in the shoe
for four weeks or until the patient was able to dorsi flex greater than 10°. Outcomes
measured included ankle range of motion, calf circumference, tendon width, plantar
flexion strength, ability to walk, ability to stand on tiptoe, time from work and re-rupture
rate. There were two re-ruptures in the operative group and five in the non-operative
group (p = 0.44). There were two major primary complications which were deep wound
operative group (mean = 9 weeks) had significantly less time away from work (p < 0.05)
than the operative group (mean = 13 weeks). There were statistically significantly more
patient-reported difficulties with shoes due to tendon broadening, and stiffness in the
ankle joint (p < 0.05) in the operative group. No other significant differences were noted
in the study.
Cetti et al (1993) completed a randomized study comparing operative (n = 56) versus
non-operative (55) treatment of Achilles tendon rupture. Patients in both groups were
immobilized in a below knee cast for four to six weeks. Outcomes included ankle range
of motion, calf circumference, subjective reports of pain, discomfort, stiffness, problems
with shoes, time off work, and resumption of sport activities, ability to stand on tiptoe,
walk, and run. There were three re-ruptures in the operative group and seven in the non
operative group (p = 0.19). The operative group had two deep wound infections and the
non-operative had one extreme residual lengthening of the tendon. The operative group
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infections. There were also 29 secondary complications in the operative group. The non
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showed statistically significantly better ankle range of motion (p = 0.002), and less calf
atrophy (p = 0.017). Minor complications were statically significantly less in the non
operative group (p = 0.004). The operative group had statistically significantly better
results for time taken to resume sport at the same level as before (0.005).
In 1997, Lo et al5‘s published results of a quantitative review comparing the treatment of
operative versus non-operative treatment of acute Achilles tendon ruptures. They
included 19 studies in their review. The overall re-rupture rate was 2.8% for the operative
studies and 11.7% for the non-operative studies (p < 0.01). The rate of minor and
moderate complications in operatively treated patients was 20 times that of non-operative
(p < 0.01). Authors were not able to conclusively recommend the optimal treatment for
an acute Achilles tendon rupture.
Moller et al (2001 )7<s published results of a prospective, randomized study comparing
operative (n = 59) and non-operative (n = 53) treatment of acute achilles tendon rupture.
Operative care was followed by early functional rehabilitation and non-operative care
was treated with plaster splintage for eight weeks. Outcomes measured included ankle
range of motion and calf circumference. Time to return to work was recorded, and time
taken to resume sports and patient opinion of treatment were recorded using the MantelHaentzel test. A visual analogue scale (VAS) was also used to evaluate the patient’s
opinion of their treatment and a functional performance was measured using a functional
index for the lower leg and ankle (FIL). Re-rupture after non-operative care was 11
(20.8%) compared with one patient (1.7%) after operative treatment (p < 0.01). The
operative group had statistically significant greater improved reported VAS quality of life
scores (p < 0.01) at eight weeks, six months, one year and two years post injury. The
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operative group also had statieally significantly less taken to return to work than the non
operative group (p = 0.06). There were 10 complications due to operative care, but none
resulted in permanent functional impairment. There were no other significant differences
in groups.
In 2002, Bhandari et alx published results of a systematic overview and meta-analysis of
treatment for acute Achilles tendon ruptures. They compared the results of randomized
and quasi-randomized trials to determine the effect of surgical versus conservative
treatment. Their primary outcome was re-rupture rate, and secondary outcomes included
eligibility criteria and three investigators independently graded study quality and
abstracted relevant information. Surgical repair significantly reduced the risk of re
rupture when compared with conservative treatment (3.1% versus 13%; RR = 0.32; 95%
Cl 0.14 to 0.71, p < 0.01). Five studies included information on infection rates (n = 421).
Infections occurred only in the surgically treated patients (4.7%). The relative risk (RR)
of infection with surgical repair was 4.6 times greater than in the cast treatment (95% Cl
1.2 to 17.8, p = 0.03). There was no significant difference in return to normal function
and spontaneous complaints found in the pooled analysis of five studies (n = 421).
Authors concluded that operative treatment significantly reduces the risk of re-rupture,
but increases the risk of complications when compare to non-operative treatment of
Achilles tendon rupture.
Weber et al (2003)'1(1completed a retrospective cohort study to describe a new non
operative protocol for Achilles tendon rupture and compare outcomes to operative
treatment. The retrospective cohort (n = 24) were treated surgically with the use of a
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deep infection rates, return to normal function, and minor complaints. Six studies met
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simple tendon suture and rehabilitated in a removable ankle-foot orthosis in neutral ankle
position and with full weight bearing as soon as tolerated. The authors consecutively
treated the prospective non-operative group (n = 23) with a slightly modified
rehabilitation protocol in an equinus ankle casting of semi-rigid tape and a removable
boot with a three centimeter wedge. The tape was removed after seven days. The patients
continued rehabilitation in a removable boot with a heel lift and were permitted full
weight bearing as soon as tolerated. Outcomes measured included ankle range of motion,
tendon length, isokinetic strength, single-leg heel raises, and a modified Thermann score
was used to record subjective and objective parameters. There was a significantly shorter
period of pain at rest (p = 0.01), a shorter period of walking with crutches (p < 0.01), and
less absence from work for the office workers (p = 0.01) in the non-operative group. All
of the other parameters showed no statistically significant differences between the
groups.
Twaddle et al (2007)106 completed a randomized, controlled trial in which they
hypothesized that there was no difference in the outcome of acute Achilles tendon rupture
treated operatively (n = 20) and non-operatively (n = 22). Following surgery, operative
patients were placed in a position of plantar flexion in a plaster of Paris cast for 10 days.
Both groups then received the same rehabilitation instructions. All patients remained non
weight bearing on crutches for six weeks. After 10 days, the cast was removed and a
below-the-knee orthosis with 20° plantar flexion was fitted. Patients were allowed to
complete instructed range of motion exercises with removal of the orthosis for five
minutes every hour. At four weeks the orthosis was brought to neutral, and at six weeks
patients were allowed to bear weight as tolerated with crutches in the orthosis. At eight
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weeks the orthosis was removed and patients were instructed to wean themselves from
the crutches. Outcome measures included calf circumference, ankle range of motion.
squeeze test reactivity, and the musculoskeletal functional assessment index (MFAI)
validated outcome score. There were two re-ruptures in the operative group and one in
the non-operative group. Authors found no significant differences in any of their
outcomes as they hypothesized.
Metz et al (2008)72 completed a randomized controlled trial to compare minimally
invasive surgery (n = 42) with non-operative treatment (n = 41) of the Achilles tendon
with immediate full weight bearing. They hypothesized that non-operative treatment with
removable orthosis as functional bracing would reduce the number of complications
compared to surgery. The operative patients were placed in a cast with the foot in plantar
flexion for one week. In the following six weeks, tape bandage was applied, supported by
a two centimeter heel raise the first two weeks; thereafter, the height was reduced to 1cm.
During the last two weeks, the heel raise was removed. Non-operative therapy consisted
of a cast in plantar flexion for one week; thereafter, a functional bracing system was
applied. In the first two weeks, the brace was fixed in 30° of plantar flexion. In the
following two weeks, bracing was in 13° of plantar flexion. In the last two weeks, the
brace was applied in a dynamic status enabling movement from neutral position to 30° of
plantar flexion. Primary outcome was the number of complications other than re-ruptures.
Secondary outcomes included time to resume work, sport participation, patient
satisfaction of treatment and pain measured with a visual analogue scale, and Leppilahti
scores which include subjective, objective assessment and isokinetic strength. There were
five re-ruptures in the non-operative group and three in the operative group (p = 0.44).
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For both groups crutches were advised in the first week of casting, thereafter it was left to
the discretion of the physician and weight bearing as tolerated. The total number of
complications on the intention-to-treat basis was 12 of 42 (29%) for surgical treatment
and 20 of 41 (49%) for non-operative treatment. The total number of complications other
than re-rupture on the inlention-to-treat basis was 9 of 42 (21%) for surgical treatment
and 15 of 41 (36%) for non-operative treatment. The operative group (59 days, ± 82) had
significantly less days off work compared to the non-operative group ( 108 days, ±115)
(difference 49 days, 95% Cl 4 to 94, p < 0.05). Authors did not find a significant
statistical difference in complication rates between groups as hypothesized.

surgical treatment, or different surgical methods for acute Achilles tendon ruptures in
adults. They included 12 trials with 844 participants. Open surgical treatment compared
with non-surgical treatment was associated with a statistically significant lower risk of re
rupture (risk ratio = 0.41, 95% Cl 0.21 to 0.77, p < 0.01), but a higher risk of other
complications including infection (RR = 4.89, 95% Cl 1.09 to 21.91 p = 0.04), adhesions
and disturbed skin sensibility (numbness). Open surgical repair was associated with a
higher risk of infection (RR = 9.32, 95% CI 1.77 to 49.16) compared to percutaneous
repair, however, the studies contained low numbers of participants.
Willits et al (2010)'12 completed a randomized trial comparing operative versus non
operative care of Achilles tendon rupture with accelerated functional rehabilitation. This
study supplied results for our retrospective cohort control group in our comparison of the
use of autologous conditioned plasma (ACP) in non-operative treatment of Achilles
tendon rupture. One hundred and forty-four patients were recruited and randomized into
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A review by Khan et al (2004)4Xevaluated the relative effects of surgical versus non-

one of the two treatment groups. All patients received a removable below-the-knee
orthosis with a two centimeter heel lift to provide approximately 20° of plantar flexion.
Patients were given crutches and told not to bear weight on the leg. At two weeks patients
were allowed to weight bear with crutches as tolerated and physiotherapy protocol began.
At six weeks the heel lift was removed and independent weight bearing as tolerated was
encouraged. The primary outcome was re-rupture rate. Secondary outcomes included
isokinetic strength, the Leppilahti score, range of motion, and calf circumference. There
were two re-ruptures in the operative group and three in the non-operative group. There
was a small but significant difference in the plantar flexion strength ratio (affected to
unaffected limb) at 2407s at one year (mean difference, 20.25%; 95% Cl, 0.07% to
40.4%; p = 0.05) and two years (mean difference, 14.15%; 95% Cl, 1.12% to 27.19%; p
= 0.03) in favor of the operative group. The side-to-side difference in plantar flexion
range of motion was greater in the non-operative group than in the operative group (mean
difference between groups, -2.21 °; 95% Cl, -3.9° to -0.5°; p = 0.01) at two years. The
authors found no definitive difference in the effectiveness of operative versus non
operative treatment specifically with the use of accelerated functional rehabilitation.
In this same study by Willits et al (2010)'l2, the authors completed a systematic review of
the literature. They pooled data from ten studies that compared operative versus non
operative treatment of Achilles tendon rupture. They further separated the studies into
those with rehabilitation with immobilization and limited weight bearing versus those
with early mobilization and weight bearing. They found lower re-rupture rates in studies
with early mobilization compared to those with immobilization as the primary
rehabilitation approach, for operative and non-operative groups.
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Summary: Of the studies we reviewed, those with significantly greater re-rupture rates
in the non-operative groups had patients immobilized in a cast for four to eight weeks as
part of their rehabilitation protocols. There appears to be no significant difference in re
rupture rates between operative and non-operative treatment for acute Achilles tendon
ruptures with accelerated functional rehabilitation protocols. Operative treatment
however, results in significantly greater complication rates than non-operative treatment.

2.4 Immobilization versus Early Mobilization
The optimal post-operative or conservative treatment rehabilitation protocol for Achilles
tendon rupture remains controversial . Early mobilization, as soon as three days post
operative, has been shown to be beneficial in studies done on rats4'. Other studies
of collagen fibers, increases tensile strength and minimizes deformation at the repair
site30' 35' H5. Traditional rehabilitation protocols have suggested six to eight weeks of
below knee cast immobilization. There is however a growing trend in the literature to
establish the benefits of early mobilization, with the recent success in studies which have
shown early mobilization to be more effective72' I03' 106‘lia 112.
Cetti et al (1994)14 completed a prospective randomized trial of patients (n = 60) with
operative treatment of Achilles tendon rupture by comparing patients using a new mobile
cast and early weight bearing (n = 30) with those using a below the knee cast (n = 30).
Outcomes included interviews where patients were asked questions about their
discomfort with the cast or mobile cast, pain, stiffness, time to work and sports activities,
shoe problems, ability to walk, and ability to stand on tiptoe. Measured outcomes
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confirmed that application of tension at the early stages of healing speeds up realignment

included calf circumference, ankle range of motion, plantar flexion strength, and
radiographic evaluation of the tendon. Sixty percent (18/60) of patients in the rigid cast
group had discomfort with their cast, and 30% (9/60) had discomfort from the mobile
cast (p < 0.01). Immediately after removal of the cast, the mobile cast group showed
greater mean range of motion (54.3° versus 29.5°) (p < 0.01). Twenty-three patients
(77%) thought that the mobile cast was excellent while six patients (20%) thought that
the rigid cast was excellent (p < 0.01). Patients in the rigid cast group showed
significantly greater atrophy (p < 0.01) than the rigid cast group. At three months the
mobile cast group showed statistically significant improved results in gait (p < 0.02),
ability to stand on toes (p < 0.03), ankle range of motion compared with contra-lateral
side (p < 0.01), normal ankle range of motion which was defined as 40°-70° plantar
flexion and 15°-30° dorsi flexion (p < 0.02), and general complaints (p < 0.05). At six
months there were statistically significant improvements of the mobile cast group for
ability to stand on toes (p = 0.01), ankle range of motion compared to contra-lateral side
(p < 0.01), and normal ankle range of motion (p < 0.02). At one year post-operative the
mobile cast showed significantly greater improvements in ankle range of motion
compared to the contra-lateral side (p < 0.01), normal ankle range of motion (p < 0.02),
and complaints (p = 0.03). At one year the mobile cast group also had significantly less
atrophy than the rigid cast group (p < 0.02). The mobile cast group showed significantly
greater calf strength at three months, six months and one year (p < 0.01). At one year
there were significantly more patients who returned to their same level of activities in the
mobile cast group (p < 0.03). There was one re-rupture in the mobile cast group and two
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re-ruptures and one infection in the rigid cast group. This study showed favorable results
of early mobilization for patients after operative treatment of Achilles tendon rupture.
McComis et al (1997)70 completed a pilot investigation in the use of a functional bracing
protocol for patients with Achilles tendon rupture who were treated non-operatively.
Fifteen patients were included in the study and followed for a mean period of 31 months.
A control group of patients from the local community were matched on age and gender to
provide normative data for the comparison of side-to-side differences. Outcomes
included a subjective questionnaire (pain, weakness, limp, sensitivity to change in
a single-limb heel-rise test. In addition, ground-reaction forces and temporal data were
assessed during functional dynamic activities that included walking, a single-limb power
hop, and a 30 second single-limb heel-rise endurance test. The study group had a mean of
2.6° greater dorsi flexion than the control group (p = 0.02). There was a weak but
significant relationship between passive dorsi flexion of the ankle and vertical force
output during gait (r = 0.40, p = 0.05); specifically, the magnitude of the difference in
vertical force output between the mid-stance and terminal-stance phases of gait increased
as the range of dorsi flexion increased. Authors concluded that their results showed non
operative functional bracing with a below knee cast to be a viable option for treatment of
Achilles tendon rupture as there were no clinically important differences found between
their study group and the matched control group. However, the low number of
individuals in the study is a limitation of the results.
Mortenson et al (1999)77 completed a prospective, randomized, controlled trial to
compare postoperative treatment with a cast for eight weeks (n = 30) or early restricted
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weather), range of motion, calf circumference, results of the Thompson squeeze test, and
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motion of the ankle in a below-the-knee brace for six weeks (n = 31), in acute operative
I

care of Achilles tendon rupture. Outcomes included calf circumference, ankle range of
motion, interviews concerning pain, stiffness, tenderness, ability to walk and run, number
of work days missed, return to sport, tiptoe standing, tendon thickness, heel raise,
isometric strength, and subjective opinion on progress and treatment. The early motion
group took significantly fewer sick days (p < 0.05) and reported greater satisfactory
subjective results (p < 0.05) than the cast group. The early motion group also reported

I

earlier time to resume sports (p < 0.01) and time until pre-injury participation level was
reached (p < 0.01). The early motion group also had significantly fewer adhesion

I

motion group had significantly less restricted range of motion (range being 0°-45° from
full dorsi to full plantar flexion) (p < 0.01), and there was still a significant difference at
12 weeks (p < 0.05). There was one re-rupture in the early motion group and two in the
cast group. This study showed favorable results for early motion protocol in the operative
treatment of Achilles tendon rupture, however, their follow up was only up till 12 weeks
and then one more follow up time with a median of 16 months.
Moller et al (2001 )76 prospectively randomized 112 patients with acute Achilles tendon
rupture, into an operative group (n = 59) with early functional rehabilitation using a
brace, and a non-operative group (n = 53) with plaster splintage for eight weeks. The
non-operative group wore a below-knee plaster cast with the ankle in equinus for four
weeks. The cast was then changed to the ankle in a neutral position. This was worn for a
further four weeks and weight-bearing allowed. The foot was placed in a below-knee
plaster and 30° equinus. The plaster was replaced by a brace 12 days later. Full weight
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complications (p < 0.01). At the time that the brace and cast was removed, the early

32

bearing and range of motion exercises were encouraged during weeks three through
eight. The brace initially prevented dorsi flexion beyond 30° of equinus. Movement to
10° of equinus was allowed at four weeks and after six weeks dorsiflexion of 10° was
permitted. A bilateral heel-raise of 15 mm for four to eight weeks and identical
rehabilitation protocols were used in both groups. Full weight-bearing without crutches
was allowed at eight weeks. Outcomes included calf circumference, ankle range of
motion, times to resume work and sports participation, a visual analogue scale (VAS) for
patient opinion of their treatment, functional index for the lower leg and ankle (FIL) to
measure functional performance, isokinetic ankle strength, and a heel raise test, There
(20.8%) (p < 0.01). There were 12 cases of complications in the operative group. There
was a significant difference in patient-reported visual analogue scale (VAS) for quality of
life at eight weeks (p < 0.01), as well as six months (p < 0.01), one year (p < 0.02), and
two years (p < 0.01). The time before return to work in the operative group was 54.9 days
(0 to 197) compared with 73.4 days (0 to 250) in the non-operative group (p = 0.06).
Authors concluded that there were no significant differences in functional outcomes, but
the high re-rupture rate in the non-operative group was significant.
Maffulli et al (2()03)fl1 completed a comparative longitudinal study of early weight
bearing versus immobilization of the surgically repaired acute Achilles tendon. Patients
in group I (n = 28) underwent immobilization with the ankle in physiological equinus for
two weeks, and in neutral for four weeks. These patients were encouraged to weight bear
on the limb as soon as tolerated. Patients in group II underwent immobilization for two
weeks with the ankle in full equinus, followed by an additional two weeks in mid
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was one re-rupture (1.7%) in the operative group and 11 in the non-operative group

equinus. Patients were advised to weight bear at this point with the ankle in neutral.
Outcome measures included calf circumference; isometric gastro-soleus strength; high
resolution real time ultrasound assessment (HRRTUS); and a questionnaire detailing
satisfaction, effect on occupational and sporting activities, and pain. Group I also
completed and additional 4-point scale which accounted for pain, difficulty in
recreational and activities of daily living, footwear restrictions, and patient satisfaction in
relation to outcome of surgery. Patients in group 1discarded their crutches significantly
earlier (p = 0.013). Number of outpatient visits were significantly less in group I (p =
0.025), and group I patients also attended significantly less physiotherapy sessions and
were discharged earlier from therapy (p = 0.008). Average time for group 1 to return to
sport was also marginally significantly less (p = 0.046). The authors concluded that there
was no adverse effect to early weight bearing following open repair of the ruptured
Achilles tendon.
Costa et al (2006)20 completed two independent randomized control trials to assess the
potential benefits of immediate weight-bearing mobilization after rupture of the Achilles
tendon. In the first trial, 48 patients consented to enter the trial with operative treatment
of their injury (n = 23 in early mobilization group, n = 25 in control group). In the second
trial, 48 patients consented to enter the trial with non-operative treatment of their injury
(n = 22 in early mobilization group, n = 26 in control group). The operative repair trial
received simple, open end-to-end repair, with the exception of two patients who were
found to have complex ruptures at operation. These patients received augmented repairs,
with a tendon lengthening procedure and bone anchors respectively. Both were followed
up on an intention-to-treat basis within their allocated treatment group. For all subjects in
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the operative trial, the limb was placed in a temporary gravity equinus plaster overnight.
Immediate mobilization in a carbon fiber orthosis with three 1.5cm heel raises were used
for the treatment group and traditional plaster cast immobilization was used in the control
group. Patients were seen every two weeks for an eight week period during which the
equinus position of the plaster or the number of heel raises in the orthosis was reduced.
The plaster cast or orthosis was removed at eight weeks.
Patients in the second trial treated non-operatively, followed the same protocol as the
first for the early mobilization and control groups respectively, with the exception of the
removal of the cast or orthosis at 12 weeks instead of eight. Patients in the treatment
group were also mobilized with full weight-bearing and encouraged to move the ankle
within the orthosis. In the second trial patients were not offered formal physiotherapy.
The primary outcome was patient-reported time taken to return to normal activity. Return
to normal sport activity, walking, stair climbing, and work activity were also recorded. In
addition, the EuroQol health status questionnaire was completed, as well as calf strength.
Five patients were lost to follow-up in both trials. There was a significant difference in
the first (operative) trial for return to walking (p = 0.03) with a median of 12.5 weeks in
the treatment group and 18 weeks in the control group. There was also a significant
reduction in the time taken to return to normal stair climbing (p = 0.02) with a median of
13 weeks in the treatment group and 22 weeks in the control group. There were two re
ruptures in the treatment group, one due to slipping on ice while in the orthosis, the other
breaching protocol and running on a treadmill too soon after removal of the orthosis.
There were six minor wound complications in the treatment group and five in the control
group. There were no significant differences in any of the outcomes for the second (non
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operative) trial. There was one re-rupture in the treatment group, and one re-rupture and
two other major complications in the control group. The authors conclude that the first
trial provides further evidence of an improved functional outcome for patients mobilized
fully weight-bearing after operative repair. The second trial did not provide evidence of a
functional benefit of immediate weight-bearing mobilization; however, the practical
advantages of early weight bearing did not predispose these patients to a higher
complication rate.
Majewski et al (2008)6< completed a comparative study on post-operative management
following percutaneous repair of acute Achilles tendon rupture. One hundred and three
patients were prospectively entered into their database. Before July 1999, 15 patients
were treated post-operatively with below-knee cast immobilization in 20° plantar flexion
with complete non-weight bearing for three weeks. This was followed by five weeks of a
below-knee walking cast with crutches. After eight weeks the cast was removed and the
patient was allowed to weight-bear during physical therapy, and gradually during daily
activities with appropriate shoes until 12 weeks. After July 1999, patients wore a splint
that held the foot in 20° plantar flexion for the first day, and after that a special shoe with
a 3cm wedge was worn during the day and the splint at night. After four weeks the
threecm wedge was reduced by one cm each week, and partial weight-bearing exercises
with bare feet were started. Patients were allowed to be full-weight bearing with crutches
as tolerated in the shoe from the beginning of the protocol. Patients were seen at 6 weeks,
12 weeks, and 12 months after surgery. Matched pairs were selected based upon gender,
age, weight, height, body mass index, and the side involved. The total number of patients
consisted of 14 matched pairs. Outcomes included range of motion, endurance (heel
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raises), return to work and sports activity, subjective outcome, Achilles tendon scores
(Hannover Achilles tendon score). For an objective endurance test, nine patients in the
cast group showed a reduction of up to 35% and 6 patients from the shoe group showed a
reduction of up to 15%. The patients immobilized in a cast (mean = 67) had significantly
(p = 0.04) longer periods away from work compared to the patients treated with early
functional therapy (mean = 37). Authors found a significant (p < 0.04) difference in
levels of restriction in sports, as compared with the level of play prior to injury in favor of
the shoe group. Patients immobilized in a cast rated their outcome significantly (p < 0.05)
concluded that their results showed early functional therapy with mobilization and full
weight bearing in a specially designed shoe provides a better clinical outcome and
enables earlier return to work and sports activities after surgery.
Suchak et al (2005)w completed a randomized study to compare the effect of early
weight-bearing with that of non-weight bearing on early post-operative recovery
following repair of an acute Achilles tendon rupture. One hundred and ten patients were
enrolled in the study and all were non-weight bearing for the first two weeks following
surgery in a posterior splint with the ankle in a relaxed equinus position. After two weeks
the posterior splint was removed and the patients were managed with a fixed-angle
hinged ankle-foot-orthosis set at the position of rest (~ 20° of plantar flexion). Patients in
both groups were instructed to gradually bring the fixed-angle hinge to 0° of plantar
flexion over the first two to three weeks. The patients were given an instruction sheet
detailing boot adjustments over two to four-day periods and what symptoms to monitor to
ensure they were not making adjustments too rapidly. All patients were taught active
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less satisfying compared to the patients treated with early functional therapy. Authors
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dorsiflexion range- of-motion exercises. Twice daily, patients removed the ankle-footorthosis and performed these range-of-motion exercises as tolerated. Patients were
randomized to either weight bearing as tolerated or non-weight bearing with crutches for
an additional four weeks. Compliance was measured with a pressure sensor in the fixedhinge ankle-foot orthosis. At six weeks patients were allowed to wean themselves from
the orthosis as tolerated. The primary outcome was the six-week postoperative healthrelated quality-of-life score with use of the RAND-36 questionnaire. Strength, range of
motion, calf circumference, single-leg heel-raises, and patient reported activities of daily
living/work/sport were also documented pre- and post-operatively. There were
(physical functioning p = 0.03, social functioning p = 0.03, vitality p = 0.04, roleemotional 0.02) at six weeks. Also at six weeks, 43% of the weight-bearing group and
9% of the non-weight bearing group reported either no limitations or limitations only
with recreational activity (p < 0.01). The results of this study showed evidence of a
benefit to weight-bearing as tolerated following operative care of Achilles tendon rupture.
Summary: Several studies support early mobilization for the operative or non-operative
treatment of Achilles tendon rupture. Early motion results in fewer functional
complications than immobilization and has shown reduced re-rupture rates for non
operative care of Achilles tendon rupture.

2.5 Platelet-rich Plasma
Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small
volume of plasma. It has also been defined as a volume of the plasma fraction of
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significantly greater scores on the RAND-36 questionnaire for the weight-bearing group
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autologous blood having a platelet concentration above baseline07. Platelet-rich plasma
(PRP) has also been referred to as, autologous conditioned plasma (ACP®), platelet
enriched plasma (PeRP), platelet-rich concentrate (PRC), autogenous platelet gel, or
platelet releasate, dependant on the commercial preparation system used, the platelet
concentration, or the anticoagulant or activator used“ . The most commonly used term
in the literature is platelet-rich plasma (PRP). For this reason (and for simplicity) we will
use PRP to mean any of these other terms throughout this review of the literature.

[

2.5.1

Histology

formed in the marrow2'90. They are the smallest of the blood cells, round or oval in shape
and approximately two pm in diameter. They lack nuclei but contain organelles and
structures such as mitochondria, microtubules, and granules (a, 5, >.) . Platelets contain
more than 30 bioactive proteins, many of which have a fundamental role in haemostasis
or tissue healing2.
Cells are able to initiate tissue repair by proliferation, a phase that involves either local
cells or undifferentiated cells migrating to the injured area through blood flow45. Since
platelets are renowned as the major sources of healing factors within blood clots, the idea
that concentrating them at the injured site could somewhat accelerate and optimize the
healing mechanisms set the rationale for the development of PRP89. PRP used in human
models is always autologous (patient obtained) and is not homologous (donor obtained)07.
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Platelets are cytoplasmic fragments of megakarocytes, a type of white blood cell, and are
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2.5.2

History in the use of PRP

Since the 1990’s, PRP has been used successfully in an array of fields of study including
maxilla-facial surgery6S and plastic surgery64. A growing body of laboratory evidence
supports the use of PRP injections for the treatment of muscle and tendon injuries and
degeneration7 l<IK. Its use in sports medicine is growing given its potential to enhance
muscle and tendon healing. In vitro and in vivo studies suggest that growth factors
released by platelets recruit reparative cells and may augment soft-tissue repair56' 56.

2.5.3

The effect of PRP on tissue

tissue and cells: ‘PRP works via the degranulation of a granules in platelets, which
contain the synthesized and prepackaged growth factors. The active secretion of these
growth factors is initiated by the clotting process of blood and begins within 10 minutes
after clotting. As the clotting process activates the platelets, the growth factors are
secreted from the cell through the cell membrane. In this process, the a granules fuse to
the platelet cell membrane where the protein growth factor is completed to a bioactive
state by the addition of histones and carbohydrate side chains to these proteins. The
secreted growth factors immediately bind to the external surface of cell membranes of
cells in the graft, flap, or wound via transmembrane receptors. These transmembrane
receptors in turn induce an activation of an endogenous internal signal protein, which
causes the expression of (unlocks) a normal gene sequence of the cell such as cellular
proliferation, matrix formation, osteoid production, collagen synthesis, etc. The
importance of this knowledge is that the PRP growth factors never enter the cell or its
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Marx et al (2004)67 effectively described the working mechanism of PRP in relation to
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nucleus, they are not mutagenic, and they act through the stimulation of normal healing,
just potentially much faster. After the initial burst of PRP-related growth factors, the
platelets synthesize and secrete additional growth factors for the remaining seven days of
their life span. Once the platelet is exhausted and dies off, the macrophage, which has
arrived in the region via the vascular in-growth stimulated by the platelets, assumes the
function of wound healing regulation by secreting some of the same growth factors as
well as others.’
Essentially, PRP acts on healing capable cells via local secretion of growth factors to
6S. Another advantage of the use of platelet-rich therapies is the antibactericidal effects of
the antibacterial and fungicidal proteins stored in platelets, which may help to prevent
infection9 The effect of PRP on tissue healing is a function of many variables,
including platelet concentration, the volume of PRP delivered, the extent and type of
injury, and the overall medical condition of the patient2. Debate continues regarding the
optimal quantity of platelets and growth factors required for muscle and tendon healing .
A platelet concentration of 1, 407, 640pl (SD 320, 100 or 10% of the PRP volume) has
been suggested to be the working definition of PRP1".A concentration four or more
times that of whole blood has also been proposed67, but lower concentrations of two to
three times that of baseline blood has also been shown to be effective in cell culture
studies17,21.

&u m u

increase their numbers (mitogenesis) and stimulate vascular ingrowth (angiogenesis)27"s2,
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2.5.4

Growth factors present in PRP and their roles

Because it is a concentration of platelets. PRP is also a concentration of the eight
fundamental protein growth factors proved to be actively secreted by platelets to initiate
all wound healing. Table 1 includes these growth factors and their functions2. Because
these concentrated platelets are suspended in a small volume of plasma, PRP is more than
just a platelet concentrate; it also contains the three proteins in blood known to act as cell
adhesion molecules for osteoconduction and as a matrix for bone, connective tissue, and
epithelial migration67. These cell adhesion molecules are fibrin itself, fibronectin, and
I u iv i i t

vitronectin67.
Table 1 Growth factors and their function
Growth Factor

Function

Platelet derived growth factor (PDGF)

Macrophage activation and angiogenesis
Fibroblast chemotaxis and proliferative
activity
Enhances collagen synthesis
Enhances the proliferation of bone cells

Vascular endothelial growth factor (VEGF) Angiogenesis
Migration and mitosis of endothelial cells
Creation of blood vessel lumen
Creates fenestrations
Chemotactic for macrophages and
granulocytes
Vasodilation (indirectly by release of
nitrous oxide)

-
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Transforming growth factor beta-1 (TGFPi)

Epidermal growth factor (EGF)
Platelet factor-4 (PF-4)

Platelet derived endothelial growth factor

Platelet derived angiogenesis factor
(PDAF)

2.5.5

fibroblasts
Induces vascularisation by stimulating
vascular endothelial cells

Preparation of PRP

Hall et al (2009)37 describes the preparation of PRP as taking a sample of autologous,
anticoagulated blood and using a centrifuge or filter to separate red blood cells from
leukocytes and platelets. Plasma is divided into platelet-poor and platelet-rich portions.
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Insulin-like growth factor-1 (IGF-1)

Enhances the proliferative activity of
fibroblasts
Stimulates biosynthesis of type I collagen
and fibronectin
Induces deposition of bone matrix
Inhibits osteoclast formation and bone
resorption
Cellular proliferation
Differentiation of epithelial cells
Stimulates the initial influx of neutrophils
into wounds
A chemoattractant for fibroblasts
A potent antiheparin agent
Chemotactic for fibroblasts and stimulates
protein synthesis
Enhances bone formation by proliferation
and differentiation of osteoblasts
Promotes wound healing by stimulating the
proliferation of kératinocytes and dermal
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The efficiency of red blood cell separation and platelet concentration is dependent on the
preparation system, but all PRP preparations contain the noncellular components of
plasma, including clotting factors.
Alsousou et al (2009)2 suggest three techniques for preparation which includes: the
gravitational platelet sequestration (GPS) technique, standard cell separators, and
autologous selective filtration technology (plateletpheresis). The GPS is a table-top
centrifuge system, whereby the anticoagualted blood is centrifuged and results in three
layers of red blood cells, white blood cells, and plasma from bottom to top respectively,
within a plastic tube. With this device, the red blood cells cannot be collected separately
and are therefore discarded. A full unit of blood is generally necessary to operate the
standard cell separators and salvage devices. In general they use a continuous-flow
centrifuge bowl or a continuous-flow disk separation technique and both a hard (fast) and
a soft (slow) spin, yielding platelet concentrations from two to four times baseline17. The
red blood cells and all or some of the platelet-poor plasma (PPP) can be returned to the
patient to maintain circulating volume11'. Selective filtration technology or
plateletpheresis depends on a single-use disposable proprietary filter designed to
concentrate platelets from whole blood. The platelets are captured on the filter and are
then harvested to provide a platelet-rich concentrate (PRC) without the need for
centrifugation. Compared to a commercial centrifuge-based method, the filtration device
produces a blood fraction similarly enriched in platelets and growth factors93.
Preparation systems are distinguished by differences such as volume of autologous blood
used, centrifuge rate/time, delivery method, activating agent, leukocyte concentration,
final PRP volume, and final platelet and growth factor concentration. Given the
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qualitative and quantitative differences, reported evidence for clinical effectiveness of
PRP cannot be generalized across preparation systems. Hematological variation between
patients (e.g. leukocyte count, platelet count) may also affect the final preparation37.

2.5.6

Delivery of PRP

PRP can be administered with or without an activating agent. Its combination with
calcium chloride and/or thrombin immediately before injection initiates platelet
activation, clot formation, and growth factor release at the injection site. Delivery of PRP
advises that clotting only be done at the time of use. Anticoagulants are used to maintain
platelet viability. Marx et al (2001 )66 also suggests the two anticoagulants that support the
metabolic needs of platelets and the viable separation of platelets in an undamaged
manner, is anticoagulant citrate dextrose-A (ACD-A) and citrate phosphate dextrose
(CPD), with the latter being the less effective of the two.
Leitner et al (2006)52 compared four different systems for the preparation of PRP which
is available commercially. These systems included Vivistat PRF Preparation Kit®, PCCS
Platelet Concentrate Collection System®, Harvest® Smart PRrP 2 APC 60 Process, and
Fibrinet® Autologous Fibrin & Platelet System. It has been shown previously that the
amount released depends on the preparation system used. The authors found Vivistat PRF
Preparation Kit, PCCS Platelet Concentrate Collective System, and Harvest SmartPReP 2
APC 60 Process all comparable in platelet yield and total amount of released PDGF-AB
after 120 h while with Fibrinet the lowest platelet yield and PDGF-AB content of
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without an exogenous activator is also commonly performed . Marx et al (2001)
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supernatant was achieved. The ability of growth factor release was equal in all four
systems.

2.5.7

PRP studies

Animal studies have been used to show the effectiveness of PRP on tendon healing as
tendon physiology is generally known to be comparative with that of humans. In the
clinical setting however, results are often not as readily transferable because the physical

2.5.7.1

Animal studies

In 2006 Virchenko et alll,x compared five treatments: (1) platelet gel, containing
thrombin-activated platelets and added calcium, (2) platelet gel supplemented with
Hirudin in order to neutralize thrombin, (3) injectable platelet concentrate without
thrombin, (4) thrombin (in saline), and (5) saline alone; in 50 Sprague-Dawley rats with
transected Achilles tendons. Outcome measures included tendon sagittal and transverse
diameters, and dynamic testing for force at failure, stiffness, and energy uptake at 10%
droop of the curve. Compared to saline, platelet gel caused a 42% increase in force at
failure (50 ± 3.7; 95% Cl 34 to 51, p < 0.01), a 90% increase in energy (159 ± 24; 95%
Cl 63 to 118, p < 0.01), and a 61% increase in ultimate stress (8.8 ± 3.4; 95% Cl 19 to
103, p < 0.01). Platelet gel with neutralized thrombin caused a 22% increase in force at
failure (43 ± 2.0; 95 % Cl 16 to 28, p < 0.01), and energy and stress were less elevated.
Injected platelet concentrate caused a 24% increase in force at failure (44 ±2.1; 95% Cl
18 to 31, p < 0.01), and thrombin caused a 10% increase (39 ± 1.1; 95 % Cl 5 to 16, p <
0.01). These effects and the differences between treatments were statistically significant.
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structure of the animals differs greatly when compared to humans.
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The PRP used in the preparation of the platelet gel was taken from 10 other rats. Authors
concluded that both platelets alone and thrombin alone can improve tendon repair in rats,
and there is an additive effect when combining them. Platelet gel showed the greatest
improvement.
Also in 2006, Virchenko and Aspenberg107 completed a randomized trial in a rat Achilles
tendon transection model where authors studied the effects of platelets on Achilles tendon
regenerates in rats three, five and 14 days after transection. They used 130 Sprague
Dawley rats. The platelet concentrate was prepared from 10 rats that were sacrificed.
randomized to receiving either the platelet or control injection. Then 20 rats were
randomized to increased loading in activity cages or the control treatment (normal cages).
They then repeated this experiment with addition of groups that received Botox and were
randomized to activity cages or control. Finally, rats were randomized to platelet
treatment or control (no treatment), and evaluated after three, five and 14 days. Outcome
measures included sagittal and transverse diameter, and dynamic loading for failure,
stiffness and energy uptake. At 14 days, unloading (with Botox) abolished any effect of
the platelets and reduced the mechanical properties of the repair tissue to less than half of
normal. Thus, some mechanical stimulation is a prerequisite for the effect of platelets at
14 days. Without Botox, both activity (force, energy, and area (p < 0.05)) and platelets
(force, stiffness, area (p < 0.05)) increased repair independently of each other. However,
at 3 and 5 days, platelets improved the mechanical properties in Botox-treated rats.
Authors concluded that mechanical stimulation combined with the use of platelets can
improve tendon healing.
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Twenty rats with unloading by Botox-induced paralysis of the calf muscles were

Kajikawa et al (2008)45 injected PRP containing various kinds of growth factors into the
wounded area of the patellar tendon of rats (n = 60), and compared the effects on
activation of circulation-derived cells and enhancement of tendon healing with a control
group (no PRP injection) (n = 20). To follow the circulation-derived cells, they used a
green fluorescent protein (GFP) chimeric rat expressing GFP in the circulating cells and
bone marrow cells. At 3 days after injury in the control group, 25.3 ± 6.3% of GFPpositive cells were proliferating. In the PRP group, the proliferation rate was significantly
higher than in the control group (56.0 ± 18.5%) (p < 0.05). At 7 days, proliferative
activity decreased in both groups, however, in the PRP group, the proliferation rate was
still significantly higher than in the control group (38.5 ± 16.3% to 17.3 ± 3.1) (p < 0.05).
In the PRP group, the numbers of heat-shock protein (HSP47; collagen-specific
molecular chaperone (-positive cells were significantly higher than in the control group at
3 and 7 days after injury. At the same time, the immunoreactivity for types I and III
collagen was higher in the PRP group than in the control group at early phase of tendon
healing. These findings suggest that locally injected PRP is useful as an activator of
circulation-derived cells for enhancement of the initial tendon healing process.

2.5.7.2

Human studies

In a cohort study, Mishra et al (2006)73 evaluated the use of (PRP) as a treatment in 20
patients with chronic severe epicondylar tendinosis. Patients were initially given a
standardized physical therapy protocol and a number of different non-operative
treatments. Patients were randomized (3:1) to a single percutaneous injection of (PRP) or
an injection of bupivacaine. They used sodium citrate as an anticoagulant, and after
centrifugation it was buffered to physiological pH using 8.4% sodium bicarbonate.
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Outcomes measures included a visual analogue scale (VAS) for pain, and a modified
Mayo elbow score. Eight weeks after the treatment, the PRP patients noted 60% (80.3 to
32.0) improvement in their visual analog pain scores versus 16% (86 to 72) improvement
in control patients (p < 0.01). |RR = 0.48 (Cl 95% 0.37 to 0.61)]. The study had a low
number of participants (n=20), with only fifteen in the PRP group and five in the control
group. After the eight week period, three of the five patients in the control group dropped
out.

treatment of chronic plantar fasciitis. Outcome measures included the visual analogue
scale (VAS) for pain, and the tenderness threshold at the plantar fascia origin using a
pressure algometer. At six weeks (p = 0.01) and three months (p < 0.01) the
corticosteroid group reported significantly lower pain scores on the visual analogue pain
scale. At six weeks, three months and six months, the corticosteroid group showed
significantly greater threshold levels (p < 0.01). However, a repeated measures test
showed no significant difference over time which included 6 weeks, 3 months and 6
months. Authors concluded that intralesional autologous blood injection is efficacious in
lowering pain and tenderness in chronic plantar fasciitis, but corticosteroid is more
superior in terms of speed and possibly extent of improvement.
In a case-control study and descriptive laboratory study, Sanchez et al (2007) evaluated
12 athletes who underwent open suture repair of acute Achilles tendon rupture. Six of
these received the repair in conjunction with a preparation rich in growth factors (PRGF).
They were compared retrospectively with six others who had only received the open
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intralesional autologous blood injection (n = 30) with corticosteroid injection (n = 31) in
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Lee et al (2007)51 completed a prospective, randomized, controlled trial to compare
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suture repair. Outcomes measured included functional outcome evaluation (time to reach
full ankle range of motion, gentle running as determined by the physician, and to resume
training activities), and cross-sectional area of the Achilles with ultrasound. Other
outcomes included ankle range of motion, complications such as infection, wound
healing defects, adhesions, sural nerve injury, and calcifications. A simplified construct
of the Cinncinati function scale was used to define the elapsed time to return to return to
sporting activities, normal training, and competition. The treatment group experienced
earlier functional restoration of ankle range of motion (7 versus 11 weeks, p = 0.03) and

cross-sectional area after a mean of 18 months compared with control subjects (p < 0.01),
as measured by ultrasonography. Authors found favorable results for PRGF and
concluded that the application of autologous PRGF may present new possibilities for
enhanced healing and functional recovery in the operative management of Achilles
tendon rupture.
In 2008 Sanchez et alX7 reported the results of their observational retrospective cohort
study where they compared the use of preparation rich in growth factors (PRGF) (n = 30)
with intra-articular hyaluronan (HA) (n = 30), in patients with osteoarthritis. Treatments
consisted of three weekly injections for both groups. Their primary outcome was the
Western Ontario and McMaster University Osteoarthritis Index (WOMAC) taken prior to
treatment and five weeks after treatments. By five weeks the PRGF group reported a
33.4% improvement in pain subscale versus 10% in the HA group (p < 0.01). There were
also significant improvements in reported physical function subscales (p = 0.43) and
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p < 0.01), as well as no wound problems. The PRGF group also had less Achilles tendon
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earlier return to jogging (11 versus 18 weeks, p = 0.04) and training (14 versus 21 weeks,
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overall WOMAC scores (p = 0.01). Authors concluded that their study had considerable
limitations, but they suggest that knee osteoarthritis treated with the application of
autologous platelet-rich fibrin could present new possibilities for enhanced outcomes.
Everts et al (2008)28 published results of a randomized controlled trial that evaluated the
use of platelet-leukocyte gel (PLG) in open subacromial decompression (OSD) surgery
for 40 patients (treatment = 20, control = 20) with chronic impingement syndrome of the
shoulder. At six weeks the PLG group showed significant improvement in VAS pain
scores which were part of the American shoulder and elbow surgeons (ASES) shoulder
medication (p < 0.01) and scored significantly better on the shoulder index score (SIS)
postoperatively (p < 0.01). Patients with PLG had significantly improved scores on the
activities of daily living (ADL) questionnaire two weeks postoperatively (p < 0.05) and
demonstrated greater range of motion improvement at two weeks (p < 0.05). Authors
concluded that the use of PLG in OSD is very effective for regaining early shoulder
function with better control of postoperative pain
Orrego et al (2008)83 performed a randomized controlled trial in 108 patients to
determine if the use of platelet concentrate (PC) and bone plug (BP) accelerates healing
in anterior cruciate ligament (ACL) reconstruction. The patients were randomized to PC
(n = 26), BP (28), combination of PC and BP (n = 27), and a control group (n = 27).
Maturation of the graft was evaluated at the femoral tunnel using MRI maturation criteria
defined by a low-intensity signal, absence of osteoligamentous interface, and no widening
of the femoral tunnel. Subjective and objective evaluations using the Lysholm and
international knee documentation committee (IKDC) scores were performed pre
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assessment method (p < 0.01). Patients with PLG also used significantly less pain
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operatively and six months after surgery. The only significant difference was found at six
months in the presence of low-intensity mature graft signal at the femoral tunnel in 78%
of the BP group and in 100% of the PC group (p = 0.04), favorable to the PC group.
Tunnel widening (negative result) was seen in 11% of the patients in the BP group versus
41% of the patients in the control group (p = 047). Authors concluded that based on their
results they were unable to find a strong clinical effect in favor of the use of PC BP.
In 2009 Silva and Sampaio95 completed a prospective study whereby 40 patients who

were sequentially enrolled into four groups: (A) control, (B) PRP in femoral tunnels at
injections at two and four weeks post-surgery, and (D) PRP activated with thrombin and
injected in the femoral tunnel at the end of surgery. Magnetic resonance imaging (MRI)
was done on all patients three months after the surgery to evaluate the signal intensity of
the fibrous interzone (FIZ) in the femoral tunnel. No significant differences between
groups were found. Authors concluded that their results showed no acceleration in tendon
healing in the use of PRP isolated or with thrombin.
Kon et al (2009)50 completed a prospective evaluation of 20 male athletes with chronic
patellar tendinosis (mean, 20.7 months) who each received three PRP injections into the
tendon at 15 day intervals. Patients were allowed to begin light activity after the second
injection and were encouraged to begin strengthening activities after the third injection.
The EQ-VAS, SF-36 Item Short Form questionnaires, and Tegner were completed by
patients before treatment, after treatments, and six months after treatment. There were no
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the end of surgery, (C) PRP in femoral tunnels at the end of surgery as well as additional
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enrolled. Their objective was to see if PRP could promote tendon-bone healing. Patients
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underwent anterior cruciate ligament reconstruction with hamstring tendon graft were
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adverse events, and all participants had significant improvements in EQ-VAS for all time
point comparisons (p < 0.01); for SF 36-Item Short Form after final treatment compared
to baseline (p < 0.01), and Tegner activity scores at the six month follow-up (p < 0.01).
Eighty percent of participants (16/20) were satisfied with their results, and 70% (14/20)
showed complete or marked functional recovery. Authors suggest that this method may
be safely used for the treatment of jumper’s knee, by aiding the regeneration of tissue
which otherwise has low healing potential.
De Vos et al (2010)24 performed a randomized controlled trial of 54 patients with chronic
randomized to receive a PRP injection (n = 27) or placebo (n = 27). The validated
Victorian Institute of Sports Assessment-Achilles (VISA-A) questionnaire, which
evaluated pain score and activity level, was completed at baseline and six, 12, and 24
weeks. Secondary outcomes included subjective patient satisfaction, return to sports, and
adherence of eccentric exercises. Authors found no statistically significant differences
between treatment groups for any of their outcomes and concluded that they were unable
to find any clinical benefit in the use of PRP in chronic mid-portion Achilles
tendinopathy.
Summary: There are currently mixed results regarding the clinical outcomes following
PRP preparations applied to injured tissue. Much more work is required to determine the
role of PRP in the treatment of soft tissue healing and specifically its effectiveness in
tendon healing after injury. As its biological benefits have been explained, the fact that it
may reduce healing time and improve strength in the musculo-tendonous complex in
acute Achilles tendon rupture still needs to be established. The availability of our
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tendinopathy two to seven centimeters above the Achilles tendon insertion. Patients were
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historical cohort gave us the opportunity to explore and compare this with a prospective
study.

54

3

Chapter 3: Study Objectives

3.1 Primary Objective
Our primary objective was to compare the isokinetic strength of the gastrocnemius-soleus
complex at one year between patients with an acute Achilles tendon rupture who received
two ACP® injections and a historical control group who received similar rehabilitation
but no ACP® injections.

U
i

Tendon Rupture Outcome Score (Leppilahti), and Ankle-Hindfoot Scale AOFAS scores.

A u v u d i

The secondary outcomes included ankle range of motion, calf circumference, Achilles
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3.2 Secondary objectives
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Chapter 4: Methods

4.1 Study design
This was a prospective cohort study with historical controls. The historical controls were
gathered from a randomized trial that compared operative versus non-operative treatment
for Achilles tendon rupture. For the purposes of our study, we used the data from the 34
patients who were randomized to the non-operative group of the randomized controlled
trial (RCT) for which there was data at one year. For the prospective cohort study, we
recruited 73 consecutive patients who were referred to our facility from emergency rooms
in London, Ontario, Canada and surrounding areas. Criteria for referral were a complete
Achilles tendon rupture upon examination at the emergency room with diagnosis by
ultrasound, presence of a palpable gap21 or Thompson Squeeze test104. One of the authors
(KW) confirmed the diagnosis at our facility within two weeks of the initial injury, and
patients signed a letter of informed consent to participate in the study. The study was
approved by the institutional research ethics board at the University of Western Ontario
(Appendix 1).
The historical cohort contained results for outcome measures at one year and two years
only. This thesis includes the analysis of outcomes at one year post-injury. The study in
its entirety includes outcome measures at six months, one year, 18 months, and two years,
and was ongoing at the time of the analysis.
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4.2 Eligibility Criteria
Eligible patients had a complete rupture of the Achilles tendon that had taken place
within 14 days of visiting our facility, were between the ages of 18 and 70 years, could
speak and understand the English language and agreed to follow the recommended
rehabilitation protocol. Patients with a significant ipsilateral injury (femur or tibia
fracture), open injury of the Achilles tendon, fluroquinolones-associated rupture (within
two weeks of injury), and avulsion of Achilles tendon from calcaneus were also
excluded. Patients who were pregnant, who had any neurological, collagen, peripheral

below knee orthosis (Aircast™ pneumatic walking brace, Figure 2) either at the
emergency room or at the initial clinic visits. The Aircast™ brace contained a two cm
heel lift providing approximately 20° of plantar flexion within the Aircast™ brace to
encourage repair of the tendon fibers in an optimal position. We instructed patients to
remain non-weight bearing and to use crutches until approximately four to six weeks post
injury. Patients were to remain in the Aircast™ brace during all activities of daily living
with the exception of bathing.

i i n n A n v

All patients (including those in the historical control group) were placed in a removable

v a w try

4.3 Treatment protocol
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vascular disease (stroke, cerebral palsy, Ehlers-Danlos), or diabetes were also excluded.
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Only
We drew approximately 12ce's of blood from the patient’s arm, which was then placed in
an Arthrex ACP® double syringe system and spun in a table-top Rotafix 32A centrifuge
(Fig 3) at 1500 rpm for five minutes. This process separated the blood components from
the plasma components into a visible three-layer consistency of red blood components
(bottom), a very thin milky white leukocyte component (middle), and yellow plasma
components (top) (Fig 4). The physician (KW) then pulled back on the syringe and
extracted only the plasma. The amount of plasma retrieved was between three and four
cc’s. The remaining fluid was discarded appropriately.

AUVUUI i

4.4 Autologous Conditioned Plasma (ACP) - Prospective Cohort
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Figure 2 AircastIM orthosis
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Figure 3 Centrifuge

Figure 4 Three-layer of plasma, leukoctyes, and
blood

Platelet
rich
plasma
Leukocyte
layer
Plateletpoor blood
The surgeon (KW) palpated and marked the gap in the ruptured Achilles tendon, then

3

sterilized and prepped the area for injection. He injected a numbing agent of Lidocaine

m

(2% concentration) superficially into the area. This was followed immediately by the
ACP® injection at the tendon gap. The second injection of ACP®, given two weeks
later, followed an identical procedure.

4.5 Physical Therapy Protocol
All patients (including the historical control group) were given a prescription to begin
physiotherapy at four weeks post injury at the clinic of their choice. We provided an
instruction sheet that detailed the rehabilitation protocol.
The protocol suggested that at two to four weeks post injury, patients could begin active
plantar and dorsi flexion to neutral, inversion/eversion below neutral, modalities to

3
3
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control swelling, knee/hip exercises as appropriate, non-weight bearing fitness or cardio
work, and hydrotherapy within motion and weight bearing limitations. At four to six
weeks activities were progressed to weight bearing as tolerated and exercises continued
as in week’s two to four. At weeks six through eight, exercises continued to include
weight bearing as tolerated, with the addition of slow dorsi flexion stretches, graduated
resistance exercises (open kinetic chain, closed kinetic chain, and functional),
proprioceptive and gait training. At eight weeks, the patient was weaned off the boot, and
continued to progress through range of motion, strength, proprioceptive, power,
endurance, increased dynamic weight bearing exercises, plyometric training, and sportspecific retraining. For the exact physical therapy protocol, please refer to Willits et al
(2010)112.
Patients returned for isokinetic strength testing, range of motion, calf circumference,
Ankle-Hindfoot AOFAS scores, and Leppilahti scores at six months and one year post
injury.

4.6 Primary Outcome - Isokinetic Strength
We chose to measure isokinetic strength, which has been shown to be reliable75 (ICCs for
plantar flexion concentric strength with hip flexion 110° and knee flexion 90° were 0.660.95).
Strength was measured using a Biodex Multi-Joint System 3 Dynamometer (Biodex
Medical, Shirley, NY) (Figure 5). We positioned the patient sitting with the hip flexed at
45°, and the knee flexed at about 30° so that the tibia and fibula were parallel to the
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ground. The thigh was supported in a thigh rest and strapped in place to prevent its use
during the testing. The medial malleolus was aligned with the dynamometer's axis of
rotation and the foot was fixed to the dynamometer footplate via two Velcro straps and a
modified ankle strap for added ankle stability. The isokinetic strength tests were
performed by three researchers who all received the same training.
Figure 5 Biodex Dynamometer
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For familiarization, patients performed submaximal practice actions at the beginning of
every testing velocity set. Participants performed three different test velocities for each
ankle that included four concentric isokinetic contractions of plantar and dorsi flexion
with maximum effort at 30°/s and 60°/s, and 10 concentric isokinetic contractions at
2407s. One minute rest was given between each test velocity. The testing was done
bilaterally with the unaffected limb first for all three velocities, followed by the affected
limb.

Peak plantar and dorsi flexion torque (N-m) were calculated by averaging peak torque
values of the contractions collected at each velocity.

4.7 Secondary Objectives
4.7.1

Leppilahti scores

The Leppilahti score is a disease-specific functional outcome measure that includes
patient ratings of pain, stiffness, calf muscle weakness, footwear restrictions, range of
motion and progress satisfaction. The isokinetic strength measures used as our primary
objective, including plantar and dorsi flexion at speeds of 307s, 607s and 2407s, are
included in the traditional scoring of the Leppilahti scale. The minimum score is 0 and
the maximum score is 100 where 100 is the best possible score.

4.7.2

Range of motion

Plantar flexion and dorsi flexion were measured using a standard goniometer with the
patient sitting on a plinth with their legs hanging relaxed over the edge of the exam table
so that the knees were flexed at 90°. We then placed the ankle in a neutral position of
approximately 90°.
The axis of rotation was the point just inferior to the lateral malleolus, and the long axis
of the fibula was used as the fixed lever arm. The moving lever arm was lined up with the
length of the fifth metatarsal. We instructed the patient to move into plantar or
dorsiflexion and the lever arm was moved accordingly to record the amount of movement
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in degrees in relation to the neutral position. This method of measurement has been
shown to be reliable (ICC=0.71-0.91 )7'\

4.7.3

Calf Circumference

Calf circumference was measured with the patient sitting at the edge of the plinth with
the lower legs relaxed. We used a standard tape measure to measure the circumference of
the calf in centimeters from approximately 15 centimeters distal to the inferior pole of the
patella, the area of largest muscle bulk in the gastrocnemius. This method of
measurement has been shown to be reliable (ICC = 0.97-0.98 )7\
Mi

4.7.4

Ankle-Hindfoot Scale (AOFAS)

Mi

»

3

The Ankle-Hindfoot Scale (AOFAS) is a region-specific quality of life and objective
functional scale. It accounts for pain, function in activities of daily living, quality of

3

range of motion and stability, and ankle alignment. It is a combination of subjective

j!

grading from the patient and objective evaluation by the physician. The questionnaire
consisted of three sections, which accounted for pain (one item of 40 points), function
(seven items of total 50), and alignment (one item of 10 points). Higher scores represent
better outcomes. For function, four of the items were subjectively answered by the patient
and three were objective evaluations by the physician. Alignment was also evaluated by
the physician. The AOFAS has demonstrated concurrent validity32,41, criterion validity41,
adequate construct validity97, and test-retest reliability41. The non-ACP® historical cohort
did not complete this form, and so these data are presented for the prospective cohort
only.

-
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Chapter 5: Statistical Analysis

There were 72 patients in the control group of the randomized trial published by Willits
et al (2010)112. Thirty-four patients had complete strength data which included seven
imputed, and were used in our analysis. We recruited 73 patients into the prospective
cohort study; 51 of these patients had complete data at one-year post-injury and were
used in the analysis. Given a conventional Type I error rate of 5%, we had about 66%
power to detect a moderate effect size of 0.5 standard deviation, which has been
suggested to represent a minimal detectable change . Given the same parameters, we
have 80% power to detect difference as small as 0.59 standard deviation.
We used independent-group t tests to make between group statistical comparisons, in
which the independent variable was the group and the dependent variable was the
continuous outcome measure (i.e., strength, Leppilahti score, ankle range of motion, or
calf circumference) at one year after treatment. A p value of less than 0.05 was
considered significant. Outcome data for each group are presented as the mean and
standard deviation, and the mean difference between groups and the 95% confidence
interval (Cl) are provided. Patients who withdrew from the study because they had
moved or who had been lost to follow-up, were excluded from the analysis. It was
believed that patients who had moved represented data that were missing completely at
random and therefore would not threaten the validity of the estimate of the treatment
effect.
For missing strength data in our historical cohort, we completed a paired samples t-test
and an intraclass correlation (ICC) to determine if we could impute data from the two
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year time point into our missing data points at one year. The paired samples t-test showed
no statistically significant difference between groups, but the ICC showed no correlation
between the complete data at one year and two year time points. We then applied a
regression method that accounted for gender, weight, age, two year strength scores,
activity at injury, and calf circumference of the involved leg. We were able to impute
data at various speeds for missing strength scores. Our analysis included 34 patients from
the historical cohort with complete data at one year.
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Chapter 6: Results

Between 2008 and 2010, we screened 83 patients. Of these, 10 were excluded; one who
refused the injection, three patients had diabetes, two were older than 70 years, two
patients had an injury that occurred longer than two weeks prior, and two patients were
excluded because they had an incomplete rupture. A total of 73 patients were entered into
our prospective study. Since that time, nine patients were lost to follow-up, one withdrew
because of wait time at their appointment, and eight patients were unavailable for their
one year visit due to unavailability to attend appointment because of work commitment
or unable to be reached. The eight who were unavailable were able to attend later
appointments in the study at 18 months and two years post-injury. Of the remaining 55
patients, two patients re-ruptured their Achilles tendon, one ruptured their contra-lateral
side, and one patient had not yet reached their one year time point at the time of this
analysis. Thus 51 patients with one year data from the ACP group was entered into our
analysis of the data.
In the historical cohort at one year, we had complete strength data for 27 patients and
imputed data for another seven patients so that we had 34 patients with strength data at
one year (See Fig 6). There were three re-ruptures.
Patients were balanced between groups for characteristics of gender, age, weight, height
and activity at time of injury (See Table 2). The average number of days post-injury that
the first ACP injection was given was 8.3 days (range 2-20 days).
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Figure 6 Flow diagrams of patient participation and data

Table 2 Demographics
Characteristics

ACP® (n = 51)

Non-ACP® (n = 34)

Gender (male : female)

43 : 8

29: 5

Age* (years)

41.5 ± 11.1

40.2 ±8.1

Height* (cm)

178.6 ±9.2

178.1 ± 10.1

Weight* (kg)

88.5 ±18.3

87.1 ± 16.4

Activity at injury (no. of

ADL4 8, Sports 42

ADL 6, Sports 28

patients)
*M ean ± S ta n d a rd deviation
yA D L = a ctiv itie s o f d a ily living
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6.1

Primary objective results

The mean isokinetie plantar flexion strength ratio (Figure 7) at 307s for the ACP group
was 87.5% (± 19.6%) and 90.5% (± 30.1%) for the historical control group. The mean
between group difference was -2.9% (95% Cl -13.6 to 7.8), p = 0.6. The mean isokinetic
plantar flexion strength ratio at 607s in the ACP group was 90.1% (± 23.6%) and 90.4%
(± 38.1%) for the historical control group. The mean between group difference was -0.3%
(95% Cl -13.6 to 13.0), p = 1.0. The mean isokinetic plantar flexion strength ratio at
2407s in the ACP group was 85.0% (± 17.8%) and 82.3% (± 27.2%) for the historical
control group. The mean between group difference was 2.7% (95% Cl -7.0 to 12.4), p =
0.6.

Figure 7 Isokinetic strength ratio percentage
Plantar flexion strength

H ACP
■ Non-ACP

lyr 3 0 %

lyr 6 0 %
Time and speed

lyr 240 %
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6.2

Secondary objective results

Comparison of between group’s side-to-side differences in plantar flexion range of
motion (ROM) where the uninjured side had greater range in both groups, was -1.1° (±
9.3°) for the ACP® group and -2.6° (± 4.6°) for the historical control group. The mean
difference between groups was 1.5° (95% Cl -1.9 to 4.9), p = 0.4. Comparison of
between group’s side-to-side differences in dorsi flexion range of motion (ROM) where
the uninjured side also had greater range in both groups, -0.9° (± 5.3) for the ACP®
group and -1.4° (± 2.8°) for the historical control group. The mean difference between
groups was 0.6° (95% Cl -1.4 to 2.5), p = 0.6.
At one year, measured side to side difference in calf circumference in the ACP® group
was -1.6cm (±1.2) and -1.6cm (± 2.0) for the historical control group, where the

)

uninjured side had greater calf circumference in both groups. The mean difference

1

between groups was -0.02 (95% Cl -0.7 to 0.7), p = 1.0.
The final scores for the Leppilahti quality of life questionnaire produced a mean of 81.2
(± 11.6) points for the ACP group and 78.1 (± 14.4) points for the historical control
group. The mean difference between groups was 3.1 points (95% Cl -2.5 to 8.7), p = 0.3.
The ankle-hindfoot AOFAS scores for the ACP® group are displayed in Table 3. As
expected, patients demonstrated the greatest improvement in the function domain over
one year. Higher scores indicate improved results.

M
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Table 3 AOFAS ankle-hindfoot scores
Item

Mean ± SD

95% Cl

6 Weeks

33.9 (5.4)

32.2-35.5

3 Months

30.9 (6.4)

29.0-32.9

6 Months

33.6 (5.7)

31.9-35.4

1 Year

36.4 (4.9)

34.9-37.8

6 Weeks

35.0 (7.6)

32.7-37.3

3 Months

41.8 (5.8)

40.0-43.6

6 Months

46.4 (2.7)

45.6-47.2

1 Year

49.0(1.4)

48.5 - 49.4

6 Weeks

9.8(1.1)

9.5 - 10.2

3 Months

10(0)

6 M o n th s

10 ( 0 )

Pain (40 points)

Function (50 points)

Alignment (10 points)
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9.7 (1.5)

9 .2 - 10.1

6 Weeks

78.7 (10.3)

75.6-81.8

3 Months

82.7 (9.8)

79.7-85.7

6 Months

90.1 (6.3)

88.1 -92.0

1 Year

95.0(5.6)

93.3 - 96.7

1 Year
Total Score (100 points)

Note: Data includes the patient who ruptured her contra-lateral side
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Chapter 7: Discussion

The use of ACP in orthopedic injuries is a relatively new concept. The literature is
limited on its use, specifically in tendon healing. Some in vivo and in vitro cell culture
studies7'45'96' 1(15 have shown ACP to he a significant activator of circulation-derived cells
for enhancement of the initial tendon healing process. This benefit has not yet been
demonstrated in the clinical setting.
In our study we found no statistically significant differences in any of our comparisons
of the prospective ACP® and historical non-ACP® groups including calf circumference,
range of motion (plantar and dorsi flexion), isokinetic strength (30°/sec, 60°/sec,
240°/sec), or Leppilahti scores. We ran the isokinetic strength analysis without the
imputed data (n = 27) in our historical control and still found no statistically significant
differences between groups.
There were two re-ruptures in the ACP® group and three in the historical non-ACP®
group (OR = 0.65, 95% Cl 0.11 to 4.00; p = 0.64). Our re-rupture rate is similar to that
observed in studies that report the re-rupture rate in operatively treated patients ’ ’ ’
We did not observe any major complications in either group.
The rehabilitation protocol employed in both groups in our study included early weight
bearing with crutches in a below-knee orthosis. Our protocol was the same as our
historical group, and the decision of the historical study by Willits et al (2010) to move
patients from immobilization to early mobilization was influenced by the work of Saleh
et al (1992)86, Gelberman et al (1990)31, McComis et al (1997)70, Maffulli et al (2003)61,

and Costa et al (2006)20. These studies showed evidence for spontaneous healing of
tendons without immobilization. There is evidence suggesting that early functional
mobilization may offer patients greater functional outcome following Achilles tendon
rupture'

. In fact, Willits et al (2010) conducted a systematic review with meta

analysis and showed that for those studies where early mobilization was included as part
of the rehabilitation protocol, the re-rupture rate in non-operatively treated patients was
similar to that observed for operatively treated patients.
The concentration of PRP obtained in our study through the Arthrex double-syringe
system is two to three times the concentration of platelets in baseline blood. This
concentration has been found effective in in vitro and in vivo studies in effective
proliferation and angiogenesis of tissue17'69, despite claims that higher concentrations
may have a greater effect77' 111.
First, Choi et al (2005) showed evidence of effective cellular viability and proliferation
with PRP concentrations of two to three times (1% to 5%) baseline blood, in their in vitro
study on bone cells. They compared various concentrations of PRP, platelet poor plasma
(PPP), and platelet concentrate on bone cells and noted the increase of cells after seven to
14 days. The lower concentrations of PRP showed a significant increase in proliferative
cells (p < 0.05), whereas greater concentrations of up to 100% approached a toxic effect
on cells.
Second, Mastrangelo et al (2011)69 found concentrations of plasma three times found in
baseline blood when compared to that of a five times concentration, did not significantly
harm the mechanical outcomes of their anterior cruciate ligament animal model. There
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were no significant differences in joint laxity at 30° (p = 0.14) and 90° (p = 0.76) of knee
flexion, but there was a significant difference at 60° (p = 0.01) favorable to the three
times concentration. There was also no significant difference in the structural properties
of the tendons (p > 0.05). The impact of the concentration of platelets on the outcome of
this study is uncertain. Thus, we are uncertain whether the concentration of PRP in our
study explains the lack of effectiveness that was observed.

7.1 Limitations
A limitation to this study is its retrospective design. However, the historical cohort group
that we selected was part of a randomized study that was led by the same authors. Thus,
unlike most retrospective designs, we are certain that eligibility criteria, protocols for
measuring outcomes and conservative treatment methods were similar between studies.
Another limitation to this study is the limited amount of patient data available to compare
at one year. Specifically, in our prospective cohort, 29% of our patients had incomplete
data. It is possible that patients with missing data are different from those with complete
data increasing the potential for a biased estimate of the treatment effect. However, of
the 21 patients with incomplete data, 8 were missing for random reasons, which in
unlikely to bias the results.
In our historical control, we imputed strength data for 7 patients at one year post injury.
To determine the validity of our imputation method, we calculated a paired t-test to
measure the magnitude of any systematic difference between one and 2 year strength data
and an ICC to measure the magnitude of the agreement between these two strength
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measurements. The paired t-test found no statistically significant systematic difference
between time points, but the ICC demonstrated low agreement between the time points
(range 0.29 to 0.67). Thus, we could not impute the missing one year strength data using
the available two year data. We then used a regression method adjusting for sex, weight,
age, two year strength scores, activity at injury, and calf circumference of the involved
leg, which showed a reasonable ability to predict the one year strength value (R“= 0.3).
Finally, we conducted the analysis with and without the imputed values and found that
the estimate of effect was similar and none of the conclusions changed.
We used the Leppilahti scale as an outcome score even though it is not a validated
outcome measure for Achilles tendon rupture. However, using this scale was necessary
because it was used in the randomized trial from which we obtained our historical cohort.
Further, the Leppilahti scale was the only available outcome measure for Achilles tendon
rupture at the time the randomized trial (and thus historical control group) data was being
collected. For our prospective cohort we also collect the AOFAS, which is a valid scale
for Achilles tendon rupture.
Patient adherence to the physiotherapy protocol was not monitored, and patients were
allowed to choose their place of treatment. As the early functional rehabilitation protocol
played an important role in the progression of the patient, it may have affected their
outcomes. However, because we are certain that the study design, data collection
protocols and rehabilitation protocols were the same between our prospective cohort and
the historical cohort; we have no reason to believe that the rate or degree of compliance
would differ between groups.

Ankle range of motion was measured with the patient in sitting with the knee at 90°
flexion. This could be considered a limitation as it would isolate the active range of
motion recorded to the action of the soleus muscle, and does not include the
gastrocnemius muscle.

7.2 Strengths
Despite the fact that the study has a retrospective design, we are certain that selection bias
(perhaps the largest potential source of bias in non-randomized designs) did not occur
since the historical control group was part of a randomized trial and both studies recruited
consecutive patients. The consecutive recruitment of patients also gives us a certainty that
our population is reflective of the type of patient with this injury.
This study was the first to compare the use of ACP® in the Achilles tendon model with
accelerated functional rehabilitation and with a patient inclusion of its size.

7.3 Summary
The results of this clinical trial suggests there is no measurable clinical benefit to the
addition of autologous conditioned plasma (ACP®) to the treatment regimen for nonoperatively treated acute Achilles tendon rupture with accelerated functional
rehabilitation. Suggestions for further studies include a randomized controlled trial, the
use of the validated Achilles tendon rupture score (ATRS), eccentric measurement of
isokinetic strength, and a more functional strength outcome measure such as tiptoe
scoring. Other suggestions for future research include the use of a PRP system that yields
a higher concentration of platelets and ACP® injections administered closer to the date of

injury during the initial inflammation healing phase, as opposed to the proliferative
phase, which may have happened in some of our patients.
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